ATLANTA, Sept. 28, 2012 (GLOBE NEWSWIRE) -- OTC Stock Review announces it has published an updated report on PositiveID Corporation (OTCBB:PSID) to its website. On September 7, 2012 PSID filed an 8-K disclosing its Chairman and CEO, William J. Caragol, invested $200,000.00 in the company. Around the same time the Department of Homeland Security (DHS) revised its strategy for its BioWatch Generation 3 program. In our opinion, the testing should prove beneficial to PSID's M-BAND system, which could alert potential strategic partners of a significant opportunity.
The DHS has split its procurement strategy into two parts that add up to spending $3 billion to put 2,500 detectors (like PSID makes) into the field. PSID's M-BAND system was developed under contract with Homeland Security. The written testimony of Office of Health Affairs Assistant Secretary and Chief Medical Officer Dr. Alexander Garza for a House Committee on Homeland Security joint Subcommittee on Emergency Preparedness, Response, and Communications and Subcommittee on Cybersecurity, Infrastructure Protection, and Security Technologies hearing titled "BioWatch Present and Future: Meeting Mission Needs for Effective Biosurveillance?" is available here http://www.dhs.gov/news/2012/09/13/written-testimony-office-health-affairs-house-committee-homeland-security-joint.
Homeland Security is under intense pressure to make our country safe. According to a September 14 ABC News release, there have been protests "in more than 20 countries from the Mideast to Southeast Asia," many of which were violent.
We wrote our initial report on PSID when it was featured in a Businessweek article about the DHS's BioWatch system. The Businessweek article can be found here http://www.businessweek.com/articles/2012-06-21/the-sky-high-price-of-sniffing-out-anthrax.
Our complete report is available at http://www.otcstockreview.com/PSID_Update.pdf.
NOTE: The purpose of this release is to introduce the reader to OTCStockReview.com and PositiveID Corporation. OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Information and opinions presented in this release are solely for informative purposes and not intended as investment advice. This document contains information obtained from public sources about PositiveID Corporation, but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of PositiveID Corporation, as profiled. OTC Stock Review has been compensated five thousand dollars by a third-party to perform investor relations services for PositiveID Corporation. Officers, directors, and employees of OTC Stock Review, may hold a position of a profiled Company and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled companies and use the terms could, would, and should. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm